Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Silvio Danese and Laurent Peyrin-Biroulet.
Silvio Danese
Connection Strength
22.860
Laurent Peyrin-Biroulet
  1. The day after COVID-19 in IBD: how to go back to 'normal'. Nat Rev Gastroenterol Hepatol. 2020 08; 17(8):441-443.
    View in: PubMed
    Score: 0.895
  2. More on Covid-19 in Immune-Mediated Inflammatory Diseases. N Engl J Med. 2020 08 20; 383(8):796.
    View in: PubMed
    Score: 0.892
  3. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019 10; 68(10):1893-1899.
    View in: PubMed
    Score: 0.829
  4. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018 09 15; 24(10):2106-2112.
    View in: PubMed
    Score: 0.786
  5. Review article: treating-to-target for inflammatory bowel disease-associated anaemia. Aliment Pharmacol Ther. 2018 09; 48(6):610-617.
    View in: PubMed
    Score: 0.779
  6. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87.
    View in: PubMed
    Score: 0.761
  7. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. J Crohns Colitis. 2017 Oct 01; 11(10):1258-1266.
    View in: PubMed
    Score: 0.736
  8. Early intervention in Crohn's disease: towards disease modification trials. Gut. 2017 12; 66(12):2179-2187.
    View in: PubMed
    Score: 0.732
  9. IBD: To switch or not to switch: that is the biosimilar question. Nat Rev Gastroenterol Hepatol. 2017 09; 14(9):508-509.
    View in: PubMed
    Score: 0.723
  10. Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. J Crohns Colitis. 2017 Jul 01; 11(7):767-768.
    View in: PubMed
    Score: 0.723
  11. Filgotinib in Crohn's Disease: JAK Is Back. Gastroenterology. 2017 Aug; 153(2):603-605.
    View in: PubMed
    Score: 0.722
  12. IBD goes home: from telemedicine to self-administered advanced therapies. Expert Opin Biol Ther. 2022 01; 22(1):17-29.
    View in: PubMed
    Score: 0.238
  13. SARS-CoV-2 vaccination in IBD: more pros than cons. Nat Rev Gastroenterol Hepatol. 2021 04; 18(4):211-213.
    View in: PubMed
    Score: 0.234
  14. Reply. Gastroenterology. 2021 05; 160(6):2223-2224.
    View in: PubMed
    Score: 0.232
  15. Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. J Crohns Colitis. 2020 Oct 21; 14(14 Suppl 3):S798-S806.
    View in: PubMed
    Score: 0.227
  16. Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. J Clin Med. 2020 Aug 20; 9(9).
    View in: PubMed
    Score: 0.225
  17. Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. Clin Gastroenterol Hepatol. 2020 11; 18(12):2689-2700.
    View in: PubMed
    Score: 0.224
  18. Reply. Clin Gastroenterol Hepatol. 2020 12; 18(13):3055.
    View in: PubMed
    Score: 0.222
  19. SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nat Rev Gastroenterol Hepatol. 2020 08; 17(8):507-516.
    View in: PubMed
    Score: 0.222
  20. Protecting patients with IBD during the COVID-19 pandemic. Lancet Gastroenterol Hepatol. 2020 07; 5(7):639.
    View in: PubMed
    Score: 0.221
  21. Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. J Clin Med. 2020 May 19; 9(5).
    View in: PubMed
    Score: 0.221
  22. Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic. Gastroenterology. 2021 01; 160(1):472-473.
    View in: PubMed
    Score: 0.221
  23. Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. Lancet Gastroenterol Hepatol. 2020 07; 5(7):631-632.
    View in: PubMed
    Score: 0.220
  24. Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. Clin Gastroenterol Hepatol. 2020 08; 18(9):2134-2135.
    View in: PubMed
    Score: 0.220
  25. Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. Gastroenterology. 2020 Jun; 158(8):2302-2304.
    View in: PubMed
    Score: 0.219
  26. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020 07; 18(8):1663-1672.
    View in: PubMed
    Score: 0.219
  27. Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019 Dec 10; 13(12):1569-1577.
    View in: PubMed
    Score: 0.214
  28. Time to include patients with ulcerative proctitis in clinical trials. Lancet Gastroenterol Hepatol. 2019 12; 4(12):900-902.
    View in: PubMed
    Score: 0.214
  29. Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"? Dig Dis Sci. 2019 11; 64(11):3035-3037.
    View in: PubMed
    Score: 0.212
  30. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol. 2019 10; 85(10):2244-2254.
    View in: PubMed
    Score: 0.209
  31. Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019 08; 4(8):643-654.
    View in: PubMed
    Score: 0.206
  32. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019; 12:1756284819848631.
    View in: PubMed
    Score: 0.206
  33. Big data in IBD: a look into the future. Nat Rev Gastroenterol Hepatol. 2019 05; 16(5):312-321.
    View in: PubMed
    Score: 0.205
  34. Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. Gastroenterology. 2019 06; 156(8):2349-2351.
    View in: PubMed
    Score: 0.205
  35. Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 11; 17(12):2397-2415.
    View in: PubMed
    Score: 0.205
  36. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy. 2019 05; 11(7):565-575.
    View in: PubMed
    Score: 0.203
  37. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Dig Dis. 2019; 37(4):266-283.
    View in: PubMed
    Score: 0.202
  38. Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. J Crohns Colitis. 2018 Nov 28; 12(12):1385-1391.
    View in: PubMed
    Score: 0.199
  39. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Dig Liver Dis. 2019 03; 51(3):327-334.
    View in: PubMed
    Score: 0.199
  40. Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis. 2018 Nov 15; 12(11):1280-1287.
    View in: PubMed
    Score: 0.199
  41. Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations. J Crohns Colitis. 2018 11 09; 12(10):1257-1258.
    View in: PubMed
    Score: 0.199
  42. Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. J Crohns Colitis. 2018 Nov 09; 12(10):1180-1190.
    View in: PubMed
    Score: 0.199
  43. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res. 2018 Oct; 16(4):522-528.
    View in: PubMed
    Score: 0.198
  44. Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes. 2019; 10(2):149-158.
    View in: PubMed
    Score: 0.197
  45. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018 09; 14(9):739-749.
    View in: PubMed
    Score: 0.196
  46. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs. 2018 Jul; 27(7):623-629.
    View in: PubMed
    Score: 0.194
  47. Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. Dig Dis. 2018; 36(5):346-353.
    View in: PubMed
    Score: 0.194
  48. Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:43-47.
    View in: PubMed
    Score: 0.193
  49. Diffusion-weighted MRI in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018 06; 3(6):433-443.
    View in: PubMed
    Score: 0.193
  50. Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:103-109.
    View in: PubMed
    Score: 0.192
  51. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:17-25.
    View in: PubMed
    Score: 0.192
  52. Infliximab biosimilar CT-P13 for inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018 06; 3(6):373-375.
    View in: PubMed
    Score: 0.190
  53. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 2018 Mar; 30(3):316-322.
    View in: PubMed
    Score: 0.189
  54. Vedolizumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2018 03; 14(3):179-189.
    View in: PubMed
    Score: 0.189
  55. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply. Aliment Pharmacol Ther. 2018 02; 47(4):540-541.
    View in: PubMed
    Score: 0.188
  56. Evolving strategies and goals of treatment in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:1-2.
    View in: PubMed
    Score: 0.188
  57. Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach! Gastroenterology. 2018 Mar; 154(4):1196-1198.
    View in: PubMed
    Score: 0.188
  58. TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice. J Crohns Colitis. 2018 Jan 24; 12(2):230-244.
    View in: PubMed
    Score: 0.188
  59. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther. 2018 Mar; 47(6):773-783.
    View in: PubMed
    Score: 0.188
  60. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 02; 47(4):454-465.
    View in: PubMed
    Score: 0.186
  61. Preventing disability in inflammatory bowel disease. Therap Adv Gastroenterol. 2017 Nov; 10(11):865-876.
    View in: PubMed
    Score: 0.184
  62. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017 Oct; 18(10):566-573.
    View in: PubMed
    Score: 0.184
  63. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017 Dec; 10(12):1363-1374.
    View in: PubMed
    Score: 0.184
  64. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
    View in: PubMed
    Score: 0.183
  65. E-health in inflammatory bowel diseases: More challenges than opportunities? Dig Liver Dis. 2017 Dec; 49(12):1320-1326.
    View in: PubMed
    Score: 0.183
  66. Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. Clin Pharmacol Ther. 2017 Oct; 102(4):633-641.
    View in: PubMed
    Score: 0.182
  67. MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. Gastroenterology. 2017 11; 153(5):1363-1377.e6.
    View in: PubMed
    Score: 0.182
  68. Novel therapeutic targets for inflammatory bowel disease. J Autoimmun. 2017 Dec; 85:103-116.
    View in: PubMed
    Score: 0.181
  69. Surgical rates in the era of biological therapy: up, down or unchanged? Curr Opin Gastroenterol. 2017 Jul; 33(4):246-253.
    View in: PubMed
    Score: 0.181
  70. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017 Jun 15; 18(6).
    View in: PubMed
    Score: 0.180
  71. Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply. Aliment Pharmacol Ther. 2017 06; 45(12):1554-1555.
    View in: PubMed
    Score: 0.180
  72. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 06; 23(6):976-985.
    View in: PubMed
    Score: 0.180
  73. Clinical development of biologicals and biosimilars - safety concerns. Expert Rev Clin Pharmacol. 2017 06; 10(6):567-569.
    View in: PubMed
    Score: 0.179
  74. Is Mesalamine Effective for the Induction of Remission in Crohn's Disease? Inflamm Bowel Dis. 2017 05; 23(5):E22-E23.
    View in: PubMed
    Score: 0.179
  75. Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. Dig Liver Dis. 2017 Aug; 49(8):864-871.
    View in: PubMed
    Score: 0.178
  76. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun. 2017 Jun; 80:10-27.
    View in: PubMed
    Score: 0.178
  77. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 05; 45(9):1179-1192.
    View in: PubMed
    Score: 0.177
  78. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 04; 45(8):1058-1072.
    View in: PubMed
    Score: 0.177
  79. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017 07; 13(7):693-703.
    View in: PubMed
    Score: 0.176
  80. Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. J Clin Med. 2020 Oct 31; 9(11).
    View in: PubMed
    Score: 0.057
  81. Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. J Crohns Colitis. 2020 10 21; 14(14 Suppl 3):S820.
    View in: PubMed
    Score: 0.057
  82. Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. J Crohns Colitis. 2020 Oct 21; 14(14 Suppl 3):S815-S819.
    View in: PubMed
    Score: 0.057
  83. A snapshot of the ongoing clinical research on COVID-19. F1000Res. 2020; 9:373.
    View in: PubMed
    Score: 0.055
  84. Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn's and Colitis Organization. Gastroenterology. 2020 Jul; 159(1):14-19.e3.
    View in: PubMed
    Score: 0.055
  85. Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis. 2019 07 17; 25(8):1399-1407.
    View in: PubMed
    Score: 0.052
  86. Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):26-31.
    View in: PubMed
    Score: 0.052
  87. Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res. 2019 08 15; 79(16):4196-4210.
    View in: PubMed
    Score: 0.052
  88. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019 10; 157(4):1032-1043.e1.
    View in: PubMed
    Score: 0.052
  89. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology. 2019 09; 157(3):647-659.e4.
    View in: PubMed
    Score: 0.051
  90. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Curr Med Chem. 2019; 26(2):259-269.
    View in: PubMed
    Score: 0.050
  91. Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clin Gastroenterol Hepatol. 2019 08; 17(9):1673-1679.e1.
    View in: PubMed
    Score: 0.050
  92. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27; 11(11):1317-1325.
    View in: PubMed
    Score: 0.046
  93. Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. United European Gastroenterol J. 2018 Mar; 6(2):310-321.
    View in: PubMed
    Score: 0.045
  94. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018 01; 67(1):53-60.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.